Posted by RENATUS, a South Korea-based pharma company pioneering next generation cyclodextrin-based therapies for the safe treatment of cholesterol-associated diseases recently filed a PCT patent application (WO2023033276) on a pharmaceutical composition comprising a gamma-cyclodextrin-based polymer for prevention or treatment of cholesterol metabolism-related diseases. In the patent application claims, Niemann-Pick disease type C, Alzheimer’s disease, Parkinson’s disease, focal segmental glomerulosclerosis (FSGS) and Alport syndrome are listed. The peculiarity of the gamma-cyclodextrin-based polymer (actually, the epichlorohydrin cross-linked polymer is discussed in detail) is minimizing cell membrane cholesterol extraction, thus exhibiting an excellent anti-inflammatory effect by causing no cytotoxicity and hemolytic activity, making intracellular cholesterol metabolism and release easy, and effectively inhibiting the release of IL-1β, MCP-1, and TNF.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023033276&_cid=P11-LF6WJ0-06736-1
The website of the company including a short introduction of the inventor and CEO, Dr. Heegon Kim has been recently launched:
https://www.renatustx.com/about
image credits: https://www.stockfreeimages.com/